Paul Tudor Jones's RNA Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 733,010 shares of Avidity Biosciences, Inc. (RNA) worth $52.87 M, representing 0.10% of the portfolio. First purchased in 2022-Q2, this medium-term investment has been held for 11 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in RNA, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 733,010 shares. Largest reduction occurred in Q3 2024, reducing 66,544 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Avidity Biosciences (RNA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Avidity Biosciences (RNA) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +733,010 | New Buy | 733,010 | $72.13 |
| Q3 2024 | -66,544 | Sold Out | 0 | $0.00 |
| Q2 2024 | -2,343 | Reduce 3.40% | 66,544 | $40.85 |
| Q1 2024 | +68,887 | New Buy | 68,887 | $25.52 |
| Q4 2023 | -35,233 | Sold Out | 0 | $0.00 |
| Q3 2023 | +20,273 | Add 135.51% | 35,233 | $6.38 |
| Q2 2023 | -2,183 | Reduce 12.73% | 14,960 | $11.09 |
| Q1 2023 | +4,367 | Add 34.18% | 17,143 | $0.02 |
| Q4 2022 | -6,957 | Reduce 35.26% | 12,776 | $0.02 |
| Q3 2022 | -4,226 | Reduce 17.64% | 19,733 | $16.32 |
| Q2 2022 | +23,959 | New Buy | 23,959 | $14.52 |
Paul Tudor Jones's Avidity Biosciences Investment FAQs
Paul Tudor Jones first purchased Avidity Biosciences, Inc. (RNA) in Q2 2022, acquiring 23,959 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Avidity Biosciences, Inc. (RNA) for 11 quarters since Q2 2022.
Paul Tudor Jones's largest addition to Avidity Biosciences, Inc. (RNA) was in Q4 2025, adding 733,010 shares worth $52.87 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 733,010 shares of Avidity Biosciences, Inc. (RNA), valued at approximately $52.87 M.
As of the Q4 2025 filing, Avidity Biosciences, Inc. (RNA) represents approximately 0.10% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Avidity Biosciences, Inc. (RNA) was 733,010 shares, as reported at the end of Q4 2025.